Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - Hortobagyi, G N; Stemmer, S M; Burris, H A (Ann Oncol, 2018)